Document Classification

Section Type: RESULTS

Text: There were no differences in plasma and urine pharmacokinetics between populations : the plasma area under the concentration-time curve over the dosing interval (from 0 to 24 h for the once-daily drug) [AUC () (ngh/mL)] and the maximum plasma concentration [C (max) (ng/mL)] ratios (with 90 % confidence intervals [CIs]) following repeat dosing with 500 g umeclidinium for HVT-PMs (as compared with HVT-NMs) were 1. 03 (0. 79-1. 34) and 0. 80 (0. 59-1. 08), respectively ; the cumulative amount of the unchanged drug excreted into the urine at 24 h (Ae (24)) [ng] ratio was 1. 01 (0. 82-1. 26).